BACKGROUND: Perinatally HIV-infected (PHIV+) adolescents and young adults (AYA) are at risk for suboptimal antiretroviral therapy (ART) adherence and mental health and substance use problems that, in HIV-infected adults, predict nonadherence. Studies on the relationship between psychiatric and substance use disorders (SUD) and adherence among PHIV+ AYA are limited, but may be important for informing evidence-based interventions to promote adherence. METHODS: Data were analyzed from 3 annual follow-up interviews (FU2-FU4, N = 179) in a longitudinal study of PHIV+ AYA. Psychiatric disorders (anxiety, disruptive behavior, mood and SUD) were assessed with the Diagnostic Interview Schedule for Children. Adherence was self-reported missed ART doses within the past week. Viral load (VL) results were abstracted from medical charts. Multiple logistic regression analyzed cross-sectional associations between psychiatric disorders and (1) missed ART dose and (2) VL > 1000 copies/mL. Multiple linear regression assessed associations between psychiatric disorders and proportion of VL values >1000 copies/mL over time. RESULTS: At FU2, 53% of PHIV+ AYA had any psychiatric disorder, 35% missed an ART dose in the past week and 47% had a VL > 1000 copies/mL. At FU2, behavioral disorders were associated with missed dose (P = 0.009) and VL > 1000 (P = 0.019), and mood disorders were associated with missed dose (P = 0.041). At FU4, behavioral disorders were associated with missed dose (P = 0.009). Behavioral disorders (P = 0.041), SUD (P = 0.016) and any disorder (P = 0.008) at FU2 were associated with higher proportion of VLs >1000 across FU2-FU4. CONCLUSIONS: Addressing psychiatric disorder and SUD among PHIV+ AYA may improve ART adherence outcomes in this population. Targeted interventions should be developed and tested.
BACKGROUND: Perinatally HIV-infected (PHIV+) adolescents and young adults (AYA) are at risk for suboptimal antiretroviral therapy (ART) adherence and mental health and substance use problems that, in HIV-infected adults, predict nonadherence. Studies on the relationship between psychiatric and substance use disorders (SUD) and adherence among PHIV+ AYA are limited, but may be important for informing evidence-based interventions to promote adherence. METHODS: Data were analyzed from 3 annual follow-up interviews (FU2-FU4, N = 179) in a longitudinal study of PHIV+ AYA. Psychiatric disorders (anxiety, disruptive behavior, mood and SUD) were assessed with the Diagnostic Interview Schedule for Children. Adherence was self-reported missed ART doses within the past week. Viral load (VL) results were abstracted from medical charts. Multiple logistic regression analyzed cross-sectional associations between psychiatric disorders and (1) missed ART dose and (2) VL > 1000 copies/mL. Multiple linear regression assessed associations between psychiatric disorders and proportion of VL values >1000 copies/mL over time. RESULTS: At FU2, 53% of PHIV+ AYA had any psychiatric disorder, 35% missed an ART dose in the past week and 47% had a VL > 1000 copies/mL. At FU2, behavioral disorders were associated with missed dose (P = 0.009) and VL > 1000 (P = 0.019), and mood disorders were associated with missed dose (P = 0.041). At FU4, behavioral disorders were associated with missed dose (P = 0.009). Behavioral disorders (P = 0.041), SUD (P = 0.016) and any disorder (P = 0.008) at FU2 were associated with higher proportion of VLs >1000 across FU2-FU4. CONCLUSIONS:Addressing psychiatric disorder and SUD among PHIV+ AYA may improve ART adherence outcomes in this population. Targeted interventions should be developed and tested.
Authors: Ann Usitalo; Erin Leister; Katherine Tassiopoulos; Susannah Allison; Kathleen Malee; Mary E Paul; Renee Smith; Russell B Van Dyke; George R Seage; Claude A Mellins Journal: AIDS Care Date: 2013-06-26
Authors: Steven A Safren; Conall O'Cleirigh; Judy Y Tan; Sudha R Raminani; Laura C Reilly; Michael W Otto; Kenneth H Mayer Journal: Health Psychol Date: 2009-01 Impact factor: 4.267
Authors: Deborah Kacanek; Yanling Huo; Kathleen Malee; Claude A Mellins; Renee Smith; Patricia A Garvie; Katherine Tassiopoulos; Sonia Lee; Claire A Berman; Mary Paul; Ana Puga; Susannah Allison Journal: AIDS Date: 2019-10-01 Impact factor: 4.177
Authors: Grace Karugaba; Gloria Thupayagale-Tshweneagae; Mary M Moleki; Onkabetse V Mabikwa; Mogomotsi Matshaba Journal: South Afr J HIV Med Date: 2022-04-29 Impact factor: 1.835
Authors: Micah McCumber; Demetria Cain; Sara LeGrand; Kenneth H Mayer; Debra A Murphy; Matthew A Psioda; Arlene C Seña; Tyrel J Starks; Michael Hudgens Journal: JMIR Res Protoc Date: 2018-12-21
Authors: Sharon L Nichols; Sean Brummel; Kathleen M Malee; Claude A Mellins; Anna-Barbara Moscicki; Renee Smith; Anai M Cuadra; Kendall Bryant; Cheryl Anne Boyce; Katherine K Tassiopoulos Journal: AIDS Behav Date: 2021-02-22
Authors: Ali Judd; Diane Melvin; Lindsay C Thompson; Caroline Foster; Marthe Le Prevost; Michael Evangeli; Alan Winston; Alejandro Arenas-Pinto; Kate Sturgeon; Katie Rowson; Diana M Gibb; Hannah Castro Journal: J Assoc Nurses AIDS Care Date: 2020 Sep-Oct Impact factor: 1.354